Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Kaplan

Showing results (61-70 of 142) with videos related to

Pageof 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 26, 2011
Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South AfricaStephen D Lawn, Lucy Campbell, Richard Kaplan, et al.
BMC Infectious Diseases|January 26, 2012
Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South AfricaMweete D Nglazi, Katharina Kranzer, Pearl Holele, et al.
Cancer Treatment Reviews|November 29, 2011
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysisClaire L Vale, Jayne F Tierney, David Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Participation of patients 65 years of age or older in cancer clinical trialsJoy H Lewis, Meredith L Kilgore, Dana P Goldman, et al.
Clinical Trials (London, England)|July 27, 2019
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization applicationAndrew Embleton-Thirsk, Elizabeth Deane, Stephen Townsend, et al.
Antiviral Therapy|August 24, 2007
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohortAndrew Boulle, Catherine Orrel, Richard Kaplan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trialsWarren B Sateren, Edward L Trimble, Jeffrey Abrams, et al.
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialPietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
AIDS (London, England)|January 26, 2017
Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infectionAlan R Lifson, Birgit Grund, Edward M Gardner, et al.
Pageof 15

Showing results (61-70 of 142) with videos related to

Sort By:
Pageof 15
Journal of Acquired Immune Deficiency Syndromes (1999)|March 26, 2011
Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South AfricaStephen D Lawn, Lucy Campbell, Richard Kaplan, et al.
BMC Infectious Diseases|January 26, 2012
Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South AfricaMweete D Nglazi, Katharina Kranzer, Pearl Holele, et al.
Cancer Treatment Reviews|November 29, 2011
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysisClaire L Vale, Jayne F Tierney, David Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Participation of patients 65 years of age or older in cancer clinical trialsJoy H Lewis, Meredith L Kilgore, Dana P Goldman, et al.
Clinical Trials (London, England)|July 27, 2019
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization applicationAndrew Embleton-Thirsk, Elizabeth Deane, Stephen Townsend, et al.
Antiviral Therapy|August 24, 2007
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohortAndrew Boulle, Catherine Orrel, Richard Kaplan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trialsWarren B Sateren, Edward L Trimble, Jeffrey Abrams, et al.
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialPietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
AIDS (London, England)|January 26, 2017
Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infectionAlan R Lifson, Birgit Grund, Edward M Gardner, et al.
Pageof 15